发明名称 |
USE OF TYPE II ANTI-CD20 ANTIBODY WITH INCREASED ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) IN COMBINATION WITH CYCLOPHOSPHAMIDE, VINCRISTINE AND DOXORUBICINE FOR TREATMENT OF NON-HODGKIN'S LYMPHOMAS |
摘要 |
<p>PROBLEM TO BE SOLVED: To manufacture a medicament for treating cancers, particularly cancers expressing CD20.SOLUTION: Type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC), in combination with one or more chemotherapeutic agents selected from the group consisting of cyclophosphamide, vincristine and doxorubicine, is used.</p> |
申请公布号 |
JP2014101370(A) |
申请公布日期 |
2014.06.05 |
申请号 |
JP20140011332 |
申请日期 |
2014.01.24 |
申请人 |
ROCHE GLYCART AG |
发明人 |
CHARLES DUMONTET;THOMAS FRIESS;FRANK HERTING;KLEIN CHRISTIAN;UMANA PABLO |
分类号 |
A61K39/395;A61K31/475;A61K31/573;A61K31/675;A61K31/704;A61P35/00;A61P43/00;C07K16/28 |
主分类号 |
A61K39/395 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|